Non-HLA antibodies in kidney allograft rejection: convincing concept in need of further evidence

Kidney Int. 2011 Mar;79(6):583-586. doi: 10.1038/ki.2010.517.

Abstract

Mostly indirect evidence suggests an important pathogenic role for non-HLA anti-endothelial cell antibodies (AECAs) in both acute and chronic rejection. The lack of standardized screening assays for AECAs unfortunately hampers the systematic collection of data in multicenter trials. Diagnostic tests based on commercially available platforms could pave the way for testing larger patient cohorts, but they still suffer from some important limitations.

Publication types

  • Comment

MeSH terms

  • Acute Disease
  • Autoantibodies / blood*
  • Biomarkers / blood
  • Drug Therapy, Combination
  • Endothelial Cells / immunology*
  • Evidence-Based Medicine
  • Fluorescent Antibody Technique, Indirect
  • Graft Rejection / immunology*
  • Graft Rejection / pathology
  • Graft Rejection / prevention & control
  • Graft Survival* / drug effects
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / immunology*
  • Predictive Value of Tests
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Autoantibodies
  • Biomarkers
  • Immunosuppressive Agents
  • anti-endothelial cell antibody